Net Sales: | | Three Months Ended, | | Twelve Months Ended | |
| | March 31, 2007 | | June 30, 2007 | | September 30, 2007 | | December 31, 2007 | | December 31, 2007 | |
| | | | | | | | | | | |
Americas | | $ | 624.5 | | $ | 661.2 | | $ | 644.7 | | $ | 728.5 | | $ | 2,658.9 | |
Europe, Middle East & Africa | | 116.0 | | 146.7 | | 133.8 | | 155.6 | | 552.1 | |
Asia Pacific | | 42.3 | | 61.4 | | 59.5 | | 62.0 | | 225.2 | |
Total reportable segments | | $ | 782.8 | | $ | 869.3 | | $ | 838.0 | | $ | 946.1 | | $ | 3,436.2 | |
| | | | | | | | | | | |
Income from Operations: | | Three Months Ended, | | Twelve Months Ended | |
| | March 31, 2007 | | June 30, 2007 | | September 30, 2007 | | December 31, 2007 | | December 31, 2007 | |
| | | | | | | | | | | |
Americas | | $ | 64.8 | A | $ | 111.5 | A | $ | 128.6 | A | $ | 142.4 | A | $ | 447.3 | A |
Europe, Middle East & Africa | | (13.3 | )B | 1.8 | B | 5.4 | B | 3.2 | B | (2.9 | )B |
Asia Pacific | | (10.8 | )C | (11.0 | )C | 0.6 | C | 1.3 | C | (19.9 | )C |
Total reportable segments | | 40.7 | | 102.3 | | 134.6 | | 146.9 | | 424.5 | |
Corporate functions | | (19.1 | )D | (18.4 | )D | (19.9 | )D | (25.1 | )D | (82.5 | )D |
Stock-based compensation | | (7.2 | ) | (16.3 | ) | (8.1 | ) | (7.8 | ) | (39.4 | ) |
Income from operations | | 14.4 | | 67.6 | | 106.6 | | 114.0 | | 302.6 | |
Interest expense and other income, net | | (29.9 | )E | (32.1 | )E | (28.5 | )E | (24.3 | )E | (114.8 | )E |
Income (loss) before income taxes | | $ | (15.5 | ) | $ | 35.5 | | $ | 78.1 | | $ | 89.7 | | $ | 187.8 | |
| | | | | | | | | | | |
Included in the reported Income (loss) before income taxes above, are the following charges: | | | | | |
| | | | | | | | | | | |
A — Americas | | | | | | | | | | | |
Mayne Pharma acquisition related: | | | | | | | | | | | |
Acquired in-process research and development | | $ | 66.2 | | $ | — | | $ | — | | $ | — | | $ | 66.2 | |
Inventories step-up charge | | 4.0 | | 6.0 | | — | | — | | 10.0 | |
Integration and other acquisition-related charges | | 4.5 | | 7.5 | | 0.9 | | 1.9 | | 14.8 | |
Intangible assets amortization | | 1.3 | | 2.0 | | 2.0 | | 2.0 | | 7.3 | |
Charges related to facilities optimization initiatives | | 9.9 | | 14.6 | | 7.6 | | 3.6 | | 35.7 | |
Intangible asset impairment for the brain-function monitoring devices | | — | | — | | — | | 7.5 | | 7.5 | |
Reduction of obligation related to the 2005 sale of the Salt Lake City, UT manufacturing plant | | — | | (1.6 | ) | — | | — | | (1.6 | ) |
Total Americas | | 85.9 | | 28.5 | | 10.5 | | 15.0 | | 139.9 | |
| | | | | | | | | | | |
B — Europe, Middle East & Africa | | | | | | | | | | | |
Mayne Pharma acquisition related: | | | | | | | | | | | |
Acquired in-process research and development | | 18.6 | | — | | — | | — | | 18.6 | |
Inventories step-up charge | | 7.0 | | 11.0 | | — | | — | | 18.0 | |
Integration and other acquisition-related charges | | 0.2 | | 0.8 | | 1.1 | | 4.3 | | 6.4 | |
Intangible assets amortization | | 1.3 | | 2.2 | | 2.1 | | 2.2 | | 7.8 | |
Charges related to facilities optimization initiatives | | 0.9 | | — | | 0.4 | | 0.6 | | 1.9 | |
Acquired in-process research and development related to product acquisition | | — | | — | | — | | 3.2 | | 3.2 | |
Total Europe, Middle East & Africa | | 28.0 | | 14.0 | | 3.6 | | 10.3 | | 55.9 | |
| | | | | | | | | | | |
C — Asia Pacific | | | | | | | | | | | |
Mayne Pharma acquisition related: | | | | | | | | | | | |
Inventories step-up charge | | 10.4 | | 14.7 | | — | | — | | 25.1 | |
Integration and other acquisition-related charges | | 0.2 | | 0.8 | | 0.9 | | 1.7 | | 3.6 | |
Intangible assets amortization | | 5.8 | | 9.0 | | 9.2 | | 8.4 | | 32.4 | |
Other acquisition-related charges | | — | | — | | 0.6 | | — | | 0.6 | |
Total Asia Pacific | | 16.4 | | 24.5 | | 10.7 | | 10.1 | | 61.7 | |
| | | | | | | | | | | |
D — Corporate functions | | | | | | | | | | | |
Integration and other acquisition-related charges | | 5.9 | | 4.4 | | 5.0 | | 4.1 | | 19.4 | |
Total Corporate functions | | 5.9 | | 4.4 | | 5.0 | | 4.1 | | 19.4 | |
| | | | | | | | | | | |
E — Interest expense and other income, net | | | | | | | | | | | |
Integration and other acquisition-related charges | | 7.9 | | — | | — | | (1.4 | ) | 6.5 | |
Total Interest expense and other income, net | | 7.9 | | — | | — | | (1.4 | ) | 6.5 | |
Total | | $ | 144.1 | | $ | 71.4 | | $ | 29.8 | | $ | 38.1 | | $ | 283.4 | |
